TAE Life Sciences Adds Seasoned Chief Operating Officer to Scale New Radiation Treatment Platform

FOOTHILL RANCH, Calif., Jan. 7, 2019 /PRNewswire/ -- TAE Life Sciences, an oncology company pioneering a new treatment platform focused on addressing limitations in current cancer therapy, is pleased to announce the appointment of Robert Hill as Chief Operating Officer. With expertise in technology development and clinical adoption in the field of Radiation Oncology, and a wealth of experience in commercializing medical technology, Hill's appointment furthers TAE Life Sciences' ability to scale its efforts to bring a compelling new technology for treating cancer patients around the world.

"Rob's strength in the innovation and commercialization of medical technology will be a great advantage as we develop the market for our innovative approach to cancer treatment," said Bruce Bauer, CEO of TAE Life Sciences. "We are excited about the knowledge and energy he brings to our team."

As Chief Operating Officer of TAE Life Sciences, Hill will use his extensive knowledge in the development of radiation oncology systems to amplify and accelerate the commercialization of a full clinical system for TAE Life Sciences' proprietary solution for Boron Neutron Capture Therapy (BNCT).

TAE Life Sciences is leveraging unique accelerator-based neutron beam technology developed by TAE Technologies, Inc., the world's largest and most advanced private fusion energy company. TAE Life Sciences has exclusively licensed intellectual property from the fusion energy leader to bring promising treatment potential for head and neck, glioblastoma multiforme (GBM) and other cancers that are difficult or impossible to treat with traditional methods. Its development of low-energy neutron beams will be practical for installation in typical hospital settings.

Hill joins from Accuray Incorporated, where he held a variety of executive level roles including Senior Vice President of R&D, Senior Vice President of Corporate Development, and Chief Product Officer. Over his tenure he led efforts in product development, innovation, mergers, acquisitions, partnerships, and intellectual property development.

Hill was previously Vice President of Engineering at North American Scientific and held various research and development leadership roles at NOMOS Corporation, where he was an early innovator in the field of radiation therapy focusing on Intensity Modulated Radiation Therapy (IMRT), Image Guided Radiation Therapy (IGRT), tomotherapy, and Monte Carlo dose calculation.

"I joined TAE Life Sciences because I believe its unique approach to cancer treatment will have a significant impact on the lives of individuals battling the most lethal cancers," said Hill. "I am honored to be joining a talented team working hard to give hope to patients and families who need new therapeutic solutions."

For more information on TAE Life Sciences and its work in bringing BNCT treatment to market, visit www.taelifesciences.com.

ABOUT TAE LIFE SCIENCES: At TAE Life Sciences, our mission is to advance Boron Neutron Capture Therapy (BNCT). Our foundational platform beam technology is derived from decades of development by TAE Technologies, Inc., an innovative leader in fusion energy technology. Leveraging their groundbreaking work for clinical investigation, TAE Life Sciences is developing the next generation of low-energy neutron beams – optimized for BNCT and practical for typical hospital settings. We have assembled a world-class, cross-functional team of clinicians, radiation oncologists, physicists and other researchers to enable us to bring our technology to those who need it most.

The device being developed by TAE Life Sciences is currently for investigational use only and has not been approved for sale or commercial use.

SOURCE TAE Life Sciences